WAIKOLOA, Hawaii — PRX100 developed by Presbyopia Therapies could be the first pharmaceutical approach for presbyopic near vision correction and may be the first new treatment to go through the FDA for presbyopia correction, according to Richard L. Lindstrom, MD, at Hawaiian Eye 2019.
PRX 100 contains aceclidine and a low dose tropicamide, Lindstrom said.
Presbyopia Therapies have determined and targeted the ideal pupil size of 1.5 mm to 1.8 mm for reduced glare and improved nighttime driving vision.
“At about 1.8 mm you start to get some negative effects of refraction,”
Uncategorized